- BNF:
- 10.1.3
- Status:
- Red
- Decision Date:
- None
Comments
Hospital use only.
Remicade (reference infliximab product), Remsima and Inflectra (biosimilars) are available.
- NICE TA329: for treating moderately to severely active ulcerative colitis after the failure of conventional therapy. (Decision date - March 2015)
- NICE TA373: for treating juvenile idiopathic arthritis (Decision date - March 2015)
- NICE TA375: for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. (Decision date - February 2016)
- NICE TA383: for ankylosing spondylitis and non-radiographic axial spondyloarthritis. (Decision date - March 2016)
- NICE TA715: Adalimumab, etanercept and infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed. (Decision date - August 2021)
- SSC2596: for refractory sarcoidosis (excluding neurosarcoidosis). NHSE commissioned. (Decision date - April 2024)
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
search again